Carl Lavie, MD
Cardiovascular Disease · New Orleans, LANPI 1891744256
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $187,241 of the $228,145 with a category attached, or 82.1%. 18 manufacturers reported payments, led by Amgen at 50.3% of the total. Reporting peaked in 2019 at $92,868 and has fallen 91.1% since, to $8,226 in 2025. Among cardiovascular disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $735.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$115K
- Sanofi-aventis U.S. LLC$54K
- Esperion Therapeutics, Inc.$27K
- AstraZeneca$12K
- Regeneron Healthcare Solutions, Inc.$11K
- Novartis$4K
- plus $6K from 12 others
What the payments were for
- Consulting fees$9,5324%
- Speaking & faculty fees$187,24182%
- Travel & lodging$22,80110%
- Food & beverage$8,5394%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 144 | $114,780 |
| Sanofi-aventis U.S. LLC | 47 | $53,546 |
| Esperion Therapeutics, Inc. | 21 | $27,378 |
| AstraZeneca | 27 | $11,680 |
| Regeneron Healthcare Solutions, Inc. | 23 | $10,556 |
| Novartis | 5 | $4,436 |
| Regeneron | 5 | $1,925 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,681 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $612 |
| Novo Nordisk | 6 | $459 |
| Kestra Medical Technology Services, Inc. | 4 | $240 |
| Abbott | 2 | $208 |
| Pfizer | 6 | $173 |
| Boston Scientific | 2 | $123 |
| Johnson & Johnson | 2 | $116 |
| Biotronik Inc. | 1 | $109 |
| Medtronic | 1 | $85 |
| GE HealthCare | 4 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$228,145 in reported general payments places this provider in the 95th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 344 | $365,435 |
| EntrestoSacubitril/Valsartan | 150 | $155,848 |
| Repatha SureclickEvolocumab | 115 | $86,169 |
| VascepaIcosapent Ethyl | 61 | $54,776 |
| NexlizetBempedoic Acid/Ezetimibe | 65 | $44,854 |
| Repatha PushtronexEvolocumab | 63 | $41,261 |
| FarxigaDapagliflozin Propanediol | 51 | $33,164 |
| JardianceEmpagliflozin | 19 | $24,480 |
| XareltoRivaroxaban | 12 | $17,131 |
| Praluent PenAlirocumab | 19 | $13,380 |
| Ezetimibe | 540 | $8,524 |
| Rosuvastatin Calcium | 366 | $6,189 |
| Atorvastatin Calcium | 643 | $5,820 |
| Metoprolol Succinate | 379 | $5,610 |
| Valsartan | 121 | $4,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $173 | $365,435344 claims |
| NovartisEntresto | $4,436 | $155,848150 claims |
| Esperion Therapeutics, Inc.Nexlizet | $27,378 | $44,85465 claims |
| AstraZenecaFarxiga | $11,680 | $33,16451 claims |
| Johnson & JohnsonXarelto | $116 | $17,13112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in New Orleans
- Keith FerdinandNew Orleans$239K
- Alexandra SanchezNew Orleans$69K
- Nabeel SaghirNew Orleans$49K
- Aimee HiltboldNew Orleans$29K
- Richard MilaniNew Orleans$28K
- Salima QamruddinNew Orleans$27K
- Joseph EnglertNew Orleans$19K
- Emmett ChapitalNew Orleans$13K
- Yvonne GillilandNew Orleans$13K
- Frank WilklowNew Orleans$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.